Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen Bets $45m Plus Up To $1.7bn On Xencor's Bi-Specifics

This article was originally published in Scrip

Executive Summary

Amgen's Blincyto (blinatumumab) was the first US FDA-approved bi-specific antibody and now the biotechnology giant may spend nearly $1.75bn on bi-specifics developed with Xencor Inc.'s XmAb platform for monoclonal antibodies that bind to two separate targets.

Advertisement

Related Content

ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register